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Hematopoietic stem cell infusion is an important procedure in Hematopoietic Stem Cell 
Transplantation (HSCT). This study identifies transfusion and other adverse reactions that can 
occur during infusion and the nursing care related to the procedure. This epidemiologic study 
used transplantations performed between 2006 and 2008. A total of 166 transplantations 
were performed: 114 were autologous, 47 allogeneic and five haploidentical. Three 
transfusion reactions and 96 adverse reactions were observed. Adverse reactions were 
related to the presence of cryoprotectant, though the infusion rate and quantity of infused 
cryoprotectant were not related to the occurrence of reactions. The products were fresh and 
infused within the recommended time when transfusion reactions occurred. In regard to 
cell source, lower engraftment time was found in peripheral blood. Nursing documentation 
is relevant for patients’ safety as well to planning an infusion in order to minimize the 
occurrence of reactions.
Descriptors: Hematopoietic Stem Cell Transplantation / Adverse Effects; Blood Component 
Transfusion; Nursing.
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Infusão de células-tronco hematopoéticas: tipos, características, 
reações adversas e transfusionais e implicações para a enfermagem
A infusão de células-tronco hematopoéticas é importante procedimento no transplante de 
células-tronco hematopoéticas. Este estudo se propôs a identificar as reações adversas 
e transfusionais que podem ocorrer durante a infusão e os cuidados de enfermagem 
inerentes ao procedimento. Trata-se de estudo epidemiológico em transplantes, ocorridos 
entre os anos 2006 e 2008. Ocorreram 166 transplantes, sendo 114 autólogos, 47 
alogênicos e 5 haploidênticos. Observaram-se três reações transfusionais e 96 reações 
adversas. As reações adversas estão ligadas à presença do crioprotetor. No entanto, 
velocidade de infusão e quantidade do crioprotetor infundido não tiveram relação com 
a ocorrência das reações. Nas reações transfusionais, os produtos eram frescos e 
infundidos na velocidade preconizada. Quanto às fontes de células, houve menor tempo 
de enxertia no sangue periférico. A documentação de enfermagem é relevante tanto 
para a segurança do paciente como para o planejamento da infusão, a fim de minimizar 
a ocorrência das reações.
Descritores: Transplante de Células-Tronco Hematopoéticas / Efeitos Adversos; Transfusão 
de Componentes Sanguíneos; Enfermagem.
Infusión de células madre hematopoyéticas: tipos, características, 
reacciones adversas y de transfusión y sus implicaciones para la 
enfermería
La infusión de las células madre hematopoyéticas es un importante procedimiento en 
el trasplante de células madre hematopoyéticas. Este estudio se propuso identificar las 
reacciones adversas y de transfusión que pueden ocurrir durante la infusión y los cuidados 
de enfermería inherentes al procedimiento. Se trata de un estudio epidemiológico 
en trasplantes ocurridos en los años de 2006 a 2008. En ese período ocurrieron 166 
trasplantes, siendo 114 autólogos, 47 alogénicos y 5 haploidénticos. Se observaron 
tres reacciones de transfusión y 96 reacciones adversas. Las reacciones adversas están 
ligadas a presencia del crioprotector. Sin embargo, la velocidad de infusión y la cantidad 
del crioprotector infundido, no tuvieron relación con la ocurrencia de las reacciones. En 
las reacciones de transfusión, los productos eran frescos e infundidos con la velocidad 
preconizada. En cuanto a las fuentes de células, hubo menor tiempo de injerto en la 
sangre periférica. La documentación de enfermería es relevante tanto para la seguridad 
del paciente como para la planificación de la infusión, a fin de minimizar la ocurrencia 
de las reacciones.
Descriptores: Trasplante de Células Madre Hematopoyéticas / Reacciones Adversas; 
Transfusión de Componentes Sanguíneos; Enfermería.
Introduction
Bone marrow is the traditional source of 
hematopoietic stem cells but is currently being replaced by 
hematopoietic progenitor cells, especially for autologous 
transplantations, which is also found in peripheral blood; 
another source is umbilical cord blood.
Being aware of the condition and measures adopted 
during the entire process of reception and storage of 
bone marrow can contribute to a safe infusion, in 
preventing, identifying, minimizing or intervening in 
potential intercurrences or complications. In the context 
of a Bone Marrow Transplantation (BMT) unit, the 
presence of a nurse is essential because a nurse, when 
appropriately qualified, can provide technical and critical 
care and assist in the event of specific complications(1).
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Given the complexity of care delivered to these 
patients, the Brazilian Federal Board of Nursing (COFEN) 
enacted Resolution 200/1997(2). It determines the 
competencies necessary for BMT nurses and one of 
these refers to specific technical procedures related to 
the aspiration and infusion of bone marrow, umbilical 
cord and peripheral blood hematopoietic precursors as 
well as planning and implementing actions aimed to 
reduce risks and optimize treatment results. Later, after 
reviewing and updating of this resolution, Resolution 
COFEN 306/2006(3) was published, which sets the rules 
for the work of nurses in hemotherapy.
Due to the risks inherent to the transfusion practice, 
one must know the incidents related to it and their 
frequency so that corrective and preventive measures 
are implemented to increase transfusion safety, which is 
the main objective of a blood-surveillance system(4).
Patients might present reactions similar to those 
of a blood transfusion(5-6) when cells are from the bone 
marrow. Transfusion reactions are negative health 
conditions that occur during or after blood transfusions. 
These can be classified as immediate or delayed, 
according to the time elapsed between the transfusion 
and the reaction(4). The ANVISA (Brazilian National 
Health Surveillance Agency) understands an immediate 
transfusion reaction to be one that occurs during 
transfusion or up to 24 hours later; and a delayed 
reaction one that occurs 24 hours or more after the 
transfusion. The most frequent signs and symptoms 
are: malaise, tremors, chills, fever (above 38º C), 
sweating, skin discoloration, myalgia, tachycardia, 
cyanosis, nausea and vomiting, among others(7).
The Hematopoietic Stem Cells (HSC) used in 
autologous transplantations are usually cryopreserved 
because the patient undergoes cell collection, on 
average, 15 days prior to hospitalization for the 
transplant, a phase known as mobilization. Hence, 
due to the prolonged time of storage and the need to 
maintain cell viability, cryopreservation is necessary. The 
complications of an infusion with HSC of cryopreserved 
marrow or peripheral blood include cardiac alterations, 
dyspnea, nausea, vomiting, allergic reactions, 
hypotension, hypertension, tremors, fever, chest pain, 
feeling of constriction in the larynx, abdominal cramps, 
and exhalation of a characteristic odor for 24 to 36 
hours. Some centers administer pre-infusion medication 
such as diphenhydramine or hydrocortisone in order to 
minimize discomfort(5,8).
Adverse events after graft infusion are reported in 
about 80% of patients(9), while nausea and vomiting are 
the most common ones(10). A study comparing reactions 
among recipients of autologous cryopreserved bone 
marrow and fresh allogeneic marrow found statistical 
significance for a higher incidence of nausea, vomiting 
and fever for the former(11). In another study, 67.36% 
of patients presented allergic and gastrointestinal 
reactions and respiratory symptoms. These occurrences 
might be associated with age, the volume infused, level 
of DMSO, total nucleated cell count and total number of 
granulocytes(12).
Dimethyl sulfoxide (DMSO) cryoprotectant is 
known for its toxic reactions, but other factors can also 
cause reactions. Thus, during infusion, nurses must 
monitor vital signs, oxygen saturation, symptoms of 
fluid overload, acute hemolytic reaction, reaction to the 
DMSO, allergic or anaphylactic reaction. If a reaction 
is perceived, the nurse must reduce or cease infusion, 
immediately report to the physician, and administer 
medication and oxygen if necessary(13).
Nurses should be informed about the source of 
cells, ABO compatibility, storage regimen, treatment 
provided to the cells and strategies of transplantation in 
order to promote high quality care.
Based on these aspects, this study was developed 
with the following objectives: to identify the types of 
transplantations performed in the studied period; to 
characterize the transplantations performed in regard 
to the donors’ and recipients’ gender, kinship, blood 
type, ABO incompatibility, and RH factor incompatibility, 
the recipients’ age, HSCT type, the cell source, interval 
between HSC collection and infusion, time for bone 
marrow engraftment, HSC treatment, quantity of 
infused DMSO, transfusion reactions, plasmapheresis in 
patient and infused volume; a goal, as well, is to identify 
the relationships among transfusions and acute adverse 
reactions and the HSCT type, HSC sources, quantity of 
infused DMSO and the volume infused.
Method
This retrospective and descriptive study collected 
data from transplantations performed from 2006 to 
2008 through records in patients’ medical files and 
databases of a university hospital and a transfusion unit 
in the interior of São Paulo, Brazil, after authorization of 
the involved institutions and approval from the Research 
Ethic Committee was obtained. Data refer to the days 
hematopoietic stem cell infusion was performed.
The following inclusion criteria were used: 
documental information for transplantations in subjects 
719
www.eerp.usp.br/rlae
Curcioli ACJV, Carvalho EC.
regardless of age; autologous transplantations for 
self-immune and hematological diseases; allogeneic 
transplantations with bone marrow or peripheral blood 
sources; transplantations with HSC, cryopreserved or 
not; transplantations performed between 2006 and 
2008. Documental information of transplantations with 
simultaneous infusion of marrow and peripheral blood 
was excluded.
The data collection instrument, tested for face and 
content validity by five judges, contained the following 
items: donor’s gender; recipient’s gender; recipient’s 
age; kinship; HSCT type; ABO/RH incompatibility; HSC 
source; HSC treatment; infused DMSO; transfusion 
reactions; plasmapheresis in patient; volume/weight 
relation; volume/weight/time relation; donor’s blood 
type and recipient’s blood type.
Information in the medical file of each patient 
was analyzed in relation to both clinical and nursing 
development, observing the presence of reactions 
during cell infusion over the first 24 hours. Adverse or 
transfusion reactions due to HSC were identified in the 
documentation of the hemotherapy service.
A database containing all studied variables was 
developed in MS Excel; variables were examined using 
descriptive statistics.
Results
According to the studied variables, the distribution of 
the types of transplantations evidenced 166 transplantations 
from relatives in the studied units between 2006 and 2008: 
114 (68.67%) autologous, 47 (28.31%) allogeneic and 
five (3.01%) haploidentical transplantations (Table 1).
Table 1 – Distribution of donors’ characteristics (gender and blood type) and recipients’ characteristics (gender, age, 





1: Male 29 (61.70%) - 0
2: Female 18 (38.30%) - 5 (100.00%)
3: Not applicable 114 (100.00%)
Recipient’s gender
1: Male 23 (48.94%) 71 (62.28%) 3 (60.00%)
2: Female 24 (51.06%) 43 (37.72%) 2 (40.00%)
Recipient’s age
1: up to 11 years old 1 (2.13%) 0 1 (20.00%)
2: 12 to 18 years old 4 (8.51%) 11 (9.65%) 2 (40.00%)
3: 19 to 40 years old 22 (46.81%) 53 (46.49%) 1 (20.00%)
4: 41 to 59 years old 19 (40.43%) 38 (33.33%) 1 (20.00%)
5: ≤ than 60 years old 1 (2.13%) 12 (10.53%)
Kinship
1: Siblings 44 (93.62%) - 0
2: Parents 3 (6.38%) - 4 (80.00%)
3: Others - 1 (20.00%)
4: Does not apply 114 (100.00%)
Donors’ blood type
1: A 19 (40.43%) - 2 (40.00%)
2: B 3 (6.38%) - 0
3: AB 1 (2.13%) - 0
4: O 24 (51.06%) - 3 (60.00%)
5: Does not apply 114 (100.00%) 0
Recipient’s blood type
1: A 16 (34.04%) - 3 (60.00%)
2: B 6 (12.77%) - 1 (20.00%)
3: AB - 0
4: O 25 (53.19%) - 1 (20.00%)
5: Does not apply 114 (100.00%) 0
Most donors in allogeneic transplantations were 
male. Females predominated in the case of haploidentical 
transplantations; mothers are the preferred donors 
in this type of HSCT, in order to minimize the risk of 
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rejection. There was a slight predominance of female 
recipients in the case of allogenic transplantations; while 
males predominated in haploidentical and autologous 
transplantations. Ages between 19 and 40 years old 
predominated for recipients both in the autologous and 
allogenic transplantations. However, the most frequent 
age range in the haploidentical transplantation was 
between 12 and 18 years old; the remaining ages were 
similar.
In relation to kinship observed in the allogeneic 
transplantation, the majority were siblings and the 
remaining were parents; mothers predominated in 
haploidentical transplantations. A high percentage of 
family members is observed in this service because it 
only performs HSCT among relatives. In regard to the 
donors’ blood type, type A and type O prevailed among 
the allogenic and haploidentical transplantations. In 
relation to the recipients’ blood type, type A and type O 
were more frequent in allogeneic transplantations. Type 
A was more frequent in haploidentical transplantations, 
equally followed by type B and O.
In the relation between HSCT and the collection 
process, time of storage and infusion rate (Table 2), the 
following were considered: storage regime, choice of the 
donor and cells source, which were defined based on the 
underlying disease and the patient’s clinical condition. 
It is observed that some of the autologous infusions 
did not present DMSO, while HSC were washed. There 
is a preference of infusing fresh products in the case 
of allogeneic and haploidentical HSCT. This is possible 
because marrow collection is scheduled for the same 
day of infusion, which is expected to diminish the chance 
of reactions.
In regard to cell source, there was a slight 
predominance of peripheral blood in the case of 
allogenic transplantations, and bone marrow in 
the case of haploidentical transplantations. Most of 
the infusions were performed with fresh products 
in allogenic transplantations, and similarly with 
the haploidentical transplantations. In the case of 
autologous transplantations, HSC were frozen due to the 
time required between collection and hospitalization for 
transplantation. Some products were washed during the 
autologous and allogenic transplantations, taking into 
account the patient’s clinical condition, usually due to a 
compromised renal function. The erythrocyte depletion 
and deplasmatization processes that occurred in the 
allogenic and haploidentical transplantations (Table 2) 
were performed due to ABO system incompatibility. Almost 
no patient in this study underwent plasmapheresis.
Table 2 – Distribution of HSCT types according to DMSO quantity; HSC sources, time of collection and treatment; 





1: up to 0.39g 6 (12.77%) 82 (71.93%) 1 (20.00%)
2: 0.40 to 0.69g 0 17 (14.91%) 0
3: 0.70 to 1.0g 0 6 (5.26%) 0
4: Not mentioned 0 6 (5.26%) 0
5: Nothing 41 (87.23%) 3 (2.63%) 4 (80.00%)
HSC sources
1: Peripheral blood 25 (53.19%) 114 (100.00%) 1 (20.00%)
2: Bone Marrow 22 (46.81%) 0 4 (80.00%)
HSC collection time
1: < q. 24h 38 (80.85%) 0 4 (80.00%)
2: 25 to 48h 2 (4.26%) 0 0
3: > 49h 7 (14.89%) 114 (100.00%) 1 (20.00%)
HSC treatment 
1: Cryopreservation 6 (12.77%) 111 (97.37%) 1 (20.00%)
2: Erythrocyte depletion 6 (12.77%) 0 0
3: Washed 2 (4.26%) 3 (2.63%) 0
4: Deplasmatization 1 (2.13%) 0 2 (40.00%)
5: None 32 (68.09%) 0 1 (20.00%)
6: Mixed treatment 0 0 1 (20.00%)
Plasmapheresis 
1:Yes 4 (8.51%) 1 (0.88%) 0
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1: up to 10 ml/min. 2 (4.26%) 67 (58.77%) 0
2: > 11 ml/min. 3 (6.38%) 37 (32.46%) 1 (20.00%)
3: Does not apply 42 (89.36%) 10 (8.77%) 4 (80.00%)
Volume/weight/time
1: up to 6ml/Kg/h 36 (76.60%) - 3 (60.00%)
2:> 7 ml/Kg/h 1 (2.13%) - 0
3: Does not apply 10 (21.28%) 114 (100.00%) 2 (40.00%)
It was observed that most of the HSC infusions 
occurred within the recommended time. It is important 
to note that the infusion rate must be controlled 
according to the characteristics of the product to be 
infused and also according to the patient’s clinical 
condition.
In regard to the distribution of incompatibilities 
and occurrence of reactions (Table 3), although 
there was a relative percentage of ABO and RH 
incompatibility, the number of transfusion reactions 
was small. It is important to keep in mind that these 
reactions were reported to the hospital transfusion 
agency by the hematologist physician present at the 
time. Adverse reactions that occurred in the infusion 
of cryopreserved products were reported by the 
physician responsible for the transfusion agency in 
a specific form from the service or by the physician 
of the bone marrow transplantation unit. There was 
12.77% of major incompatibility in the allogenic 
transplantations. RH incompatibility, both major 
(4.26%) and minor (4.26%), occurred in the allogenic 
HSCT. In this situation, the marrow bag needs to be 






1: Yes. major 6 (12.77%) -
2: Yes. minor 4 (8.51%) - 2 (40.00%)
3: No 34 (72.34%) - 2 (40.00%)
4: bidirectional 3 (6.38%) - 1 (20.00%)
Incompatibility RH
1: Yes. major 2 (4.26%) -
2: Yes. minor 2 (4.26%) -
3: No 43 (91.49%) - 5 (100.00%)
Transfusion Reactions
1:Yes 3 (6.38%)
2: No 41 (87.23%) 114 (100.00%) 5 (100.00%)
3: Not mentioned 3 (6.38%) 0
Adverse Reactions
1:Yes 10 (21.27%) 84 (73.68%) 2 (40.00%)
2: No 37 (78.72%) 30 (26.32%) 3 (60.00%)
Table 3 – Distribution of the HSCT type according to ABO and RH incompatibility, transfusion and adverse reactions 
in cell infusion. Ribeirão Preto, Brazil 2009
We opt for considering adverse reactions as those 
reactions presented during the cryopreserved HSC 
infusion due to the association with the cryoprotectant. 
Although such reactions also occurred during allogenic 
HSCT (21.27%), they were more frequent (73.68%) 
in autologous HSCT. It was observed that transfusion 
reactions occurred with fresh products, while 66.67% 
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Table 4 – Distribution of transfusion and adverse 
reactions according to DMSO quantity, HSC sources, 
relation volume/weight/time and volume/time of 
infusion. Ribeirão Preto, Brazil 2009
Variable Transfusion Reaction Adverse Reaction
DMSO
1: up to 0.39g - 66 (68.75%)
2: 0.40 to 0.69g - 15 (15.62%)
3: 0.70 to 1.0g - 5 (5.20%)
4: Not mentioned - 5 (5.20%)
5: Nothing 3 (100.00%) 5 (5.20%)
HSC sources
1: Peripheral blood 1 (33.33%) 47 (67.61%)
2: Bone Marrow 2 (66.67%) 23 (32.39%)
Volume/weight/time
1: up to 6ml/Kg/h 3 (100.00%) -
2: > 7 ml/Kg/h 0 -
Volume/time
1: up to 10 ml/min. - 50 (52.08%)
2: > 11 ml/min. - 33 (34.37%)
3: Does not apply - 13 (13.54%)
Among the adverse reactions, 68.75% occurred 
in infusions with smaller quantities of DMSO. A total of 
96.84% of patients whose cell source was peripheral blood 
had adverse reactions; reactions were also observed in 
patients whose cell source was bone marrow.
In regard to the infusion rate, even patients 
(52.08%) with autologous transplantation who were 
infused at a rate of up to 10ml/min presented adverse 
reactions; 34.37% of patients had a faster rate of 
infusion and also developed such reactions.
Discussion
The distribution of transplantation types observed 
in this study is corroborated by data from the Brazilian 
Registry of Transplantation, which indicates that the 
number of autologous transplantations was greater than 
the number of the allogenic type in the first quarter of 
2009. Transplantation from relatives is still prevalent 
when compared to non-relative transplantation, 
which has increased in recent years(14). The recipients’ 
characteristics concerning age range and gender are 
related to their pathology.
Findings regarding the donors’ gender are similar 
to national(14) ones and to those of one study carried out 
in Turkey with a marked prevalence of male recipients in 
autologous transplantations(15).
The obtained incidence of blood type derives 
from data from the Brazilian Association of Organ 
Transplantation (ABTO) in which type O occurs in 49% 
of cases and type A occurs in 33% of organ and tissue 
donors (Table 1).
In the case of ABO incompatibility between donor 
and recipient, transplantation is subject to some 
complications: acute hemolysis, delayed erythropoiesis, 
late hemolysis, among others(8); and depletion of red 
blood cells should be considered in order to minimize the 
occurrence of hemolytic reactions(16). The inheritance of 
blood group antigens does not depend on inheritance of 
major histocompatibility antigen (HLA). Incompatibility of 
the ABO system does not define transplantation success 
because the clinical importance lies in HLA compatibility. 
The HSC donor and recipient can have different blood 
groups and still present HLA compatibility(8).
Major incompatibility was identified in this study 
in a discreet number of allogenic transplantations 
and minor incompatibility in some haploidentical 
transplantations (Table 3). Major ABO incompatibility 
is relevant information for nurses who will perform 
cell infusions. In this type of transplantation, the bag 
erythrocyte depletion occurs and nurses must verify the 
final number of red blood cells at the time s/he receives 
the product. This volume can trigger the occurrence of 
a transfusion reaction if not within the permitted limits, 
that is, less than 0.5ml/kg of the recipient’s weight(17). In 
the event of minor ABO incompatibility, the marrow bag 
has to be deplasmatized so that antibody supernatants 
are withdrawn from the plasma.
Incompatibility involving the Rh system can lead 
to late alloimmune hemolysis (major incompatibility) 
and hemolysis in 10% to 15% of patients (minor type). 
Rh incompatibility was not observed in almost all 
transplantations.
The occurrence of reactions during HSC infusion 
can also be related to its source, total volume, cell 
treatment, use of cryoprotectant (DMSO), ABO 
compatibility and infusion rate. In this study (Table 2) 
the major source of stem cells for the autologous and 
allogenic transplantations was peripheral blood, with 
time of collection less than 24 hours before the infusion 
for the allogenic and haploidentical transplantations and 
more than 49 hours before infusion for the autologous 
transplantations; cells were not treated in most of 
the allogeneic transplantations; cryopreservation was 
performed in almost all the autologous transplantations; 
deplasmatization and cryopreservation were observed 
in some haploidentical transplantations; there was no 
plasmapheresis in the majority of patients in the allogeneic 
transplantations; infusion rates were up to 10ml/min 
predominated in the autologous transplantation and 
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up to 6ml/kg/hour in the allogenic and haploidentical 
transplantation.
One hypothesis for the development of adverse 
reactions related to the infusion of thawed graft is the 
amount of DMSO administered; in products in which 
DMSO was depleted, this relation of HSC volume infused 
is attributed to the residual amount of DMSO and to the 
number of granulocytes presented(14).
In this study, data of transfusion or adverse reactions 
in relation to the presence of DMSO, the volume infused 
and cell source, indicated that the three transfusion 
reactions occurred with the use of products without 
DMSO, when peripheral blood or marrow cells were the 
source, when the infusion rate was up to 6ml/kg/hour. 
The adverse reactions occurred predominantly with the 
use of products with up to 0.39g of DMSO, peripheral 
blood and in infusions of up to 10ml/hour (52.08%) 
(Table 4). The concentration of DMSO generally used, 
between 5% and 10%, ensures the viability of cells 
and graft capacity. The maximum recommended dose 
of DMSO to be infused is 1g/kg or 10ml/kg of DMSO 
solutions at 10%(18).
Given the severity and high incidence of adverse 
reactions, one possible preventive measure is washing 
the cells with cell washers in order to remove DMSO, 
free hemoglobin and cellular debris. In this study, 
washed cells were used in five transplantations due to 
the patients’ clinical conditions and the cryoprotectant’s 
potential toxicity. The plasmapheresis procedure aims 
to reduce the anti-A or anti-B hemagglutinins presence 
in the recipient’s plasma. The antibody titer in the 
patient’s blood is usually high in the case of multiple 
transfusions. The major disadvantage of this method 
is the risk of transfusion reactions due to the use of 
fresh frozen plasma in replacing the volume of removed 
plasma(19).
During cell infusion, products containing HSC 
cannot be irradiated or transfused with equipment with 
leukoreduction because these procedures can harm or 
eliminate cells. In addition, it is necessary to minimize 
the contact of cells with DMSO, which would lead to a 
faster infusion. To determine infusion rate, the volume 
of cells in relation to the patient’s volume of blood, 
quantity of DMSO in the product and the product’s 
temperature should be taken into account. The 
recommended infusion for products with DMSO at 10% 
is between 5 to 20ml/min(6). For patients that receive 
non-frozen bone marrow, the following parameters are 
recommended since transfusion reactions common to 
other blood products can develop(12). In this study, a 
slight majority of patients who presented adverse 
reactions were infused at up to 10ml/min. The infusion 
of blood products is performed at a rate of 3 to 6 ml/
kg/hour, though it can be slower in the case of more 
vulnerable individuals, at 1ml/kg/hour(17). All the 
patients who presented transfusion reactions were 
infused at up to 6 ml/kg/h (Table 4).
The conclusion regarding the occurrence of 
transfusion reactions is that these occurred in infusions 
with fresh products (without DMSO), of peripheral blood 
and bone marrow sources, while infusion rate followed 
the recommendations in the literature. Most adverse 
reactions occurred in autologous transplantations, 
all from peripheral blood sources. A larger number of 
reactions occurred with smaller quantities of DMSO and 
in infusions in which the infusion rate was performed as 
recommended.
Being aware, trained and attentive to prevent, 
identify, address and treat potential transfusion reactions 
is the duty of all health professionals dealing with 
transfusions(4,8). In addition to the service organization(20), 
the importance of the organization of care is highlighted, 
especially in relation to the documentation of information 
and organization of clinical data. These aspects favor 
the efficient recording of rational and objective decision-
making, revealing care appropriate to the needs of 
patients(21), as well as promoting the prevention or early 
identification of other adverse events related to the 
devices used in transfusions such as the central venous 
catheter whose rate of adverse events, though rare in 
the hospital setting(22), can compromise the cell infusion 
procedure. From this perspective, this study supports 
nurses’ clinical rationale in improving the safety of 
patients in the context of transfusion care because it 
identifies variables of interest in HSCT situations and 
related adverse and transfusion reactions.
Final Considerations
As evidenced in this study, reactions can occur 
with fresh or cryoprotectant products, originating from 
peripheral or bone marrow sources, even when infused 
within the recommended rate. The adoption of strategies 
that lead nurses to know the conditions of the process 
of collection, treatment and storage of products to be 
infused promotes the observation of adverse and/or 
transfusion reactions and facilitates their identification. 
In addition, recording the entire infusion process enables 
understanding nursing care delivery and favors control 
of adverse events that occur during HSC infusion.
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